Categories: NewsPharmaceutical

Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2023 Financial Results on March 21, 2024

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

RESEARCH TRIANGLE PARK, N.C., March 19, 2024 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its full year and fourth quarter 2023 financial results before the opening of the U.S. financial markets on Thursday, March 21, 2024. Management will host a conference call and webcast that day to discuss the Company’s financial and business results.

Conference Call & Webcast Detail:

Date:
Time:
Link:
Thursday, March 21, 2024
8:30 a.m. Eastern Time
https://register.vevent.com/register/BI02e7eebc14074ab296653cd5d988a0a1

To access the conference call, please register using https://register.vevent.com/register/BI02e7eebc14074ab296653cd5d988a0a1. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto www.fennepharma.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. A webcast replay of the conference call will also be archived on www.fennecpharma.com for thirty days.

About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of PEDMARK® and Pedmarqsi to reduce the risk of platinum-induced ototoxicity in pediatric patients. Further, PEDMARK received FDA approval in September 2022 and European Commission Marketing Authorization in June 2023 for Pedmarqsi. PEDMARK has received Orphan Drug Exclusivity in the U.S. for seven years of market protection and Pedmarqsi has received Pediatric Use Marketing Authorization in Europe which includes eight years plus two years of data and market protection. For more information, please visit www.fennecpharma.com.

For further information, please contact:
Investors:
Robert Andrade
Chief Financial Officer
Fennec Pharmaceuticals Inc.
+1 919-246-5299

Corporate and Media:
Lindsay Rocco
Elixir Health Public Relations
+1 862-596-1304
lrocco@elixirhealthpr.com

Staff

Recent Posts

CORRECTING and REPLACING Vouched Developing Integration in Epic Toolbox Under Construction for Remote Identity Verification

Integration Empowers Hospitals to Streamline Patient Onboarding, Enhance Compliance, and Improve Care Delivery with Seamless…

6 hours ago

BLUE & CO., LLC PROVIDES NOTICE OF DATA EVENT

CARMEL, Ind., July 3, 2025 /PRNewswire/ -- Blue & Co., LLC ("Blue") is a financial…

9 hours ago

Dr. Aubrey de Grey Brings Cutting-Edge Science to RAADfest 2025: LEV Foundation Partners with Coalition for Radical Life Extension

Renowned biogerontologist Dr. Aubrey de Grey to curate specialized scientific programming at world's leading longevity…

9 hours ago

NervGen Strengthens Board Leadership to Accelerate Clinical and Corporate Growth

Dr. Adam Rogers appointed chair as company advances toward key milestones following positive topline chronic…

10 hours ago

ScienceSoft Raises the Bar for AI Voice Scheduling in Healthcare

MCKINNEY, Texas--(BUSINESS WIRE)--#AI--Human-Like, Real-Time AI Scheduler launched by ScienceSoft ScienceSoft has introduced a HIPAA-compliant AI…

12 hours ago

New Podcast “Spreading the Good BUZZ” Hosted by Josh and Heidi Case Launches July 7th with Explosive Global Reach and a Mission to Transform Lives

Through Hope and Community in Recovery, Sober.Buzz along with @SoberBuzzToken on Instagram are Impacting and…

15 hours ago